Demand is growing for cell culture supplements that are safer, more consistent, and free of animal-derived components. In both academic research and clinical manufacturing, fetal bovine serum (FBS), long considered the standard supplement for cell expansion, is increasingly being replaced by human-derived alternatives. Among these alternatives, human platelet lysate (hPL) has emerged as a strong option because it is rich in growth factors and well suited to human cell culture.
More recent hPL formulations include heparin-free, GMP-grade options designed to support animal component–free workflows in translational applications. This development supports safer workflow design, stronger regulatory compliance, and improved batch-to-batch consistency for scalable bioproduction.
Human Platelet Lysate (hPL) is a cell culture supplement produced from platelet-rich plasma (PRP), collected from screened human donors. During processing, platelets are lysed to release a rich mix of growth-promoting biomolecules, including platelet-derived growth factor (PDGF), transforming growth factor-beta (TGF-β), epidermal growth factor (EGF), and basic fibroblast growth factor (bFGF).
These signaling molecules support important cellular activities such as proliferation, adhesion, and differentiation, making hPL useful for culturing primary human cells such as mesenchymal stromal cells (MSCs), immune cells, and endothelial cells.
Compared with FBS, hPL reduces species- related concerns and provides a more physiologically relevant environment for human cells. This can support strong cell growth, morphology maintenance, and reproducibility across experiments and manufacturing runs.
hPL naturally contains fibrinogen and coagulation factors from platelet-rich plasma. When added to calcium-containing basal media, these components can trigger fibrin polymerization, forming gels or clots that make the medium unusable. Heparin‑free human platelet lysate (hPL) is a fibrinogen‑depleted form of hPL that no longer requires the heparin to prevent clot or gel formation in culture medium, while still supporting robust cell expansion.
“GMP-grade” refers to Good Manufacturing Practice; a quality framework used in the production of materials intended for use in clinical or therapeutic workflows. For hPL, GMP manufacturing is intended to support:
These measures help distinguish GMP-grade hPL from research-grade alternatives. While both may perform similarly in cell growth assays, GMP-grade production provides the documentation and manufacturing controls needed for integration into cell therapy manufacturing pipelines, GMP-compliant labs, and regulated bioproduction environments.
Heparin-free, GMP-grade hPL is suited for a wide range of applications where safety, reproducibility, and regulatory alignment are high priorities:
Compared with 10% FBS, the 5% hPL-MP (GMP Grade) supported improved hUC-MSC culture performance, with faster doubling time, higher cell density, more uniform fibroblast-like morphology, and more cohesive monolayer formation. These findings demonstrate the strong potential of hPL-MP as an effective supplement for robust and consistent hUC-MSC expansion.
These findings demonstrate the strong potential of hPL-MP as an effective supplement for robust and consistent hUC-MSC expansion.
The shift toward human-derived, xeno-free culture systems marks an important step in biotechnology and regenerative medicine. Heparin-free, GMP-grade hPL offers provides researchers and manufacturers a more practical, ethically aligned option with a scientifically validated, regulatory-aligned, and ethical solution for high-performance cell culture.
By removing the need for porcine-derived heparin and supporting GMP-based manufacturing, this next-generation supplement helps organizations scale from bench research to into more controlled translational workflows.
For scientists seeking to modernize their workflows, heparin-free hPL can provide a stronger foundation for consistent success in cell culture and translational bioproduction.
For cell culture workflows that require a human-derived, animal component-free supplement, choosing a heparin-free, GMP-grade hPL can support greater process consistency, simplified media preparation, and better alignment with translational and manufacturing needs.
